The Economics of Reproducibility in Preclinical Research

Area of Science:

• Life Science Research
• Drug Development
• Biomedical Science

Background:

• Low reproducibility in life science research hinders scientific progress and increases drug development costs.
• Over 50% of preclinical research is irreproducible, representing a significant financial burden.
• Irreproducible research leads to wasted resources and delays in discovering effective therapies.

Purpose of the Study:

• To address the critical issue of low reproducibility in life science research.
• To present a framework for improving the reliability of preclinical research findings.
• To accelerate the development of life-saving therapies by enhancing research reproducibility.

Main Methods:

• Analysis of past studies on research reproducibility.
• Identification of key factors contributing to irreproducibility in preclinical research.
• Development of a framework and strategic plan for long-term improvements.

Main Results:

• The cumulative prevalence of irreproducible preclinical research exceeds 50%.
• The annual cost of irreproducible preclinical research in the US is approximately $28 billion.
• A framework for enhancing reproducibility has been outlined.

Conclusions:

• Improving research reproducibility is essential for scientific advancement and efficient drug development.
• Implementing the proposed framework can lead to significant cost savings and faster therapeutic discoveries.
• Addressing irreproducibility will accelerate the delivery of life-saving treatments to patients.